Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
 |
 |
 |
|
||
 |
|
 |
|
||
products
Our lead compound crofelemer is under development for 4 distinct product indications:
- CRO-IBS for Diarrhea-Predominant IBS (D-IBS)
- CRO-HIV for AIDS-related diarrhea
- CRO-ID for Acute infectious diarrhea
- CRO-PED for Pediatric diarrhea
The FDA has granted fast-track status to CRO-IBS and CRO-HIV.